Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

China Medical System Acquires Luqa Ventures, a China Dermatology Company

publication date: Feb 8, 2021

China Medical System of Shenzhen acquired Luqa Ventures, a Shanghai dermatology company, at an undisclosed price. Both companies in-license products for China's market. Founded in 2010, Luqa has developed a portfolio of aesthetic products, both OTC and prescription offerings. CMS said Luqa's portfolio would expand its own dermatology offerings and establish CMS as a provider of medical aesthetic products for the first time. Luqa's product lineup includes prescription drugs, medical devices, medical aesthetic solutions and skin care products. More details....

Stock Symbol: (HK: 0867)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.